Latest Biotechnology, Pharmaceutical and Healthcare News from BioPortfolio

08:06 EDT 21st October 2018 | BioPortfolio

Here are the most relevant search results for "BioPortfolio" found in our extensive news archives from over 250 global news sources.

More Information about BioPortfolio on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about BioPortfolio for you to read. Along with our medical data and news we also list BioPortfolio Clinical Trials, which are updated daily. BioPortfolio also has a large database of BioPortfolio Companies for you to search.

Showing News Articles 1–25 of 4,700+ from BioPortfolio

Tuesday 16th October 2018

Locate Therapeutics announces name change to Locate Bio and new investment from Mercia Technologies PLC

 16 October 2018:  Locate Bio Limited (“Locate” or “Company”) a specialist regenerative medicine company based in Nottingham, UK, today announces that it has changed its name from Locate Therapeutics Limited and received a new direct investment of £0.5 million from Mercia Technologies PLC (AIM: MERC) (“Mercia”). The Company’s chang...

Thursday 4th October 2018

Consensus Orthopedics to discuss connected health technology at the ISTA 31st Annual Congress

Lunch symposium featuring TracPatch® wearable technology for <!--LGfEGNT2Lhm-->healthcare October 4, 2018 El Dorado Hills, CA – Consensus Orthopedics, Inc. (“Consensus”), a global medical technology and <!--LGfEGNT2Lhm-->joint reconstruction company, is scheduled to participate in the 31st Annual Congress of the International Society of Technology (ISTA)...

Wednesday 26th September 2018

Major London Hospital uses ProtoCOL 3 Automated Colony Counter To Rapidly and Accurately Track Spread of Antibiotic Resistant Superbugs

Cambridge, UK: Synbiosis, a long-established, expert manufacturer of automated microbiological systems, is pleased to announce its ProtoCOL 3 automated colony counter is being used at a major teaching hospital in London to accurately track the spread of Carbapenem-Resistant bacteria (CRB) superbugs. Microbiologists in the infection control group at the hospital are using ProtoCOL 3 to count co...

Monday 24th September 2018

Ferring Pharmaceuticals Announces UK Launch of Testavan® (testosterone 2% gel) for the Treatment of Male Hypogonadism

West Drayton, England, UK – 24 September, 2018 – Ferring Pharmaceuticals today announced the launch of Testavan® 20 mg/g transdermal gel for the treatment of adult male hypogonadism. Testavan® is a new testosterone replacement therapy designed to restore testosterone levels to a normal range (300–1050 ng/dL) in adult males with hypogonadism. Male hypogonadism (or low...

Wednesday 19th September 2018

ECVAM evaluation of GARDskin rescheduled to an extra scientific committee meeting in spring 2019

Lund, September 18, 2018 - SenzaGen (Nasdaq First North: SENZA) has been notified by the European Center for the Validation of Alternative Methods (ECVAM) authority that due to time constrains their scientific committee (ESAC) will not be able to evaluate tests in the category ”Test Guidelines on Health Effects”, to which GARDskin belongs, this year. The authority cites high workload...

SenzaGen launches the first in vitro airway allergy test – GARDair – at ESTIV2018

Lund, September 18, 2018 - SenzaGen (Nasdaq First North: SENZA) announced today that the company will launch GARDair, the first in vitro test for airway allergies at ESTIV2018, the 20th International Congress on In Vitro Toxicology. Removing the need for animal testing and opening a completely new market, GARDair is based on the company’s proprietary GARD® technology platform. Using ge...

Monday 10th September 2018

flutiform(R) k-haler(R), a Novel Treatment for Adolescents and Adults with Asthma, now Available in Europe

flutiform k-haler is now available in Europe as an asthma treatment for adults and adolescents (aged 12 years and older)[1] Research indicates that many patients make errors with their inhalers and this is associated with poor asthma control and increased exacerbations[2] The k-haler device is a simple breath-actuated, or breath-triggered, inhaler, ICS/LABA combination inhaler desi...

Ilya Pharma raises additional Euros 3 million for novel ATMP trials

Fast-growing Swedish biologics specialist Ilya Pharma raises additional Euro 3 million to take novel ATMP through to Phase II for wound care September 10th 2018: Ilya Pharma today announced that is has now raised an additional Euros 3 million in a new targeted share issue. The funds will facilitate continued growth and take the company through the first clinical study and planning of the up...

Tuesday 4th September 2018

HeartSciences Named Among ‘50 Smartest Companies of the Year 2018’ by The Silicon Review Magazine

Southlake, Texas – September 4, 2018 – Silicon Review, a leading Business and Technology magazine has named HeartSciences, as one of the 50 Smartest Companies of the Year 2018. “The Silicon Review 50 Smartest Companies of the Year 2018 program identifies companies that mastered the discipline of smartness and stood high among the crowd,” said Sreshtha Banerjee, Editor...

Monday 20th August 2018

Lytix Biopharma AS appoints Gjest Breistein as the new CFO

20th August 2018: Lytix Biopharma today announces that Torbjørn Furuseth has stepped down as Chief Financial Officer. Gjest Breistein, who has served as Business Controller in Lytix Biopharma since August 2017, will succeed him. Mr. Breistein has eight years of experience from PwC as an auditor and consultant in the capital markets group advising clients in capital market transaction...

Thursday 16th August 2018

Leaf Expression Systems appoints Simon Saxby as new Chief Executive Officer

15th August 2018: Norwich, UK: Leaf Expression Systems, a contract biopharmaceutical development business specialising in plant-based expression of proteins, metabolites and complex natural products, announced today that life sciences veteran Simon J.Y Saxby has joined the company as Chief Executive Officer. The appointment comes as Leaf Expression System’s multi-million pound purpose-b...

Wednesday 15th August 2018

A1M Pharma to prioritize the indication acute kidney injuries in further development of ROSgard™ on the basis of positive preclinical data

August 15th 2018: A1M Pharma is today announcing the company’s decision to prioritize the indication acute kidney injuries in conjunction with heart surgery in the long-term clinical development plan for the drug candidate ROSgard™. This decision is based on the recently communicated positive results from preclinical studies in relevant research models. After completion of a Phase...

First Wave Launches First Sales into Korea & Taiwan - Establishes Foothold in Asian Markets

  August 15, 2018 – Batavia, New York – First Wave Products Group, LLC, a subsidiary of First Wave Technologies, Inc. (“First Wave” and “company”), announced an expansion of the company’s international presence into the APAC region—including South Korea and Taiwan.  First Wave is now serving clients at a global level and furthering i...

Tuesday 14th August 2018

AIM Pharma appoints CMO as clinic nears for ROSgard™ kidney protection drug

August 14th 2018: A1M Pharma announces that the company has appointed Tobias Larsson Agervald as its new Chief Medical Officer (CMO). Tobias Larsson Agervald is an associated professor and specialist in internal medicine and nephrology with extensive experience in global research and development of pharmaceuticals in both early and later clinical stages. He will assume the position on Decembe...

Friday 10th August 2018

A1M Pharma’s candidate drug ROSgard™ shows protective effect against acute kidney injury in US study

A1M Pharma AB (publ), 556755-3226 Press release 2018-08-10. A1M Pharma announces that the company's candidate drug ROSgard™ shows a strong protective effect against acute kidney injury (AKI) in a preclinical study conducted in the USA in collaboration with Indiana University. The positive results correlate well with recently reported results from a similar study conducted in Euro...

Thursday 9th August 2018

Immunovia`s blood-based IMMray™ biomarker array provides highly accurate diagnosis of non-small cell lung cancer in a new collaborative study with a major global pharma company

August 9th 2019 LUND, SWEDEN ― Immunovia AB announced today that in a new collaborative study with a major global pharma company, Immunovia ́s innovative blood-based testing platform, IMMray™ could differentiate healthy controls from non-small cell lung cancer (NSCLC) samples with a 95 % accuracy. Accounting for nearly 14% of all new cancers, NSCLC is one of the top three cancer type...

Tuesday 31st July 2018

US Patent granted for Follicum's FOL005 protein-based hair restoration product

31st July 2018: Follicum AB ("Follicum") announces that the U.S. Patent Office (USPTO) has issued a Notice of Allowance for their patent application 15/184,290 which is the company’s second, follow-up application which when granted confers expanded protection for Follicum's product candidate FOL-005. Follicum has already an approved US patent in this patent family, speci...

Monday 23rd July 2018

Following Investment, MedPharm Ltd Strengthens its Board with Three New Members

  July 23rd 2018: MedPharm Ltd., a leading provider of contract topical and transdermal product design and formulation development services, is pleased to introduce three new members to its Board of Directors. MedPharm has announced the appointment of three new members to its Board of Directors following an investment by Ampersand Capital Partners (“Ampersand”) in the Com...

A1M Pharma reports positive results from preclinical study in acute kidney injuries

July 23rd 2018: A1M Pharma today reports positive results from a preclinical study in the field of acute kidney injury (AKI). The primary endpoints show that the active substance in the company’s candidate drug, ROSgard™, significantly reduces the damaging effects on kidneys following exposure to severe oxidative stress. The study is a stage in A1M Pharma’s previously anno...

Tuesday 17th July 2018

First Wave Brings on Ken Rutt as Strategic Consultant

  Expertise Supports Development of the CLARITY-IA™ Respirator July 17, 2018 – Batavia, New York – Medical Conservation Device, a subsidiary of First Wave Technologies, Inc. (“First Wave” and “company”), announces that the company has engaged the consulting services of Ken Rutt, a senior level mechanical engineer and project engineer with o...

Thursday 28th June 2018

Consensus Orthopedics Featured in Q2 2018 Emerging Medical Technologies Spotlight

June 28, 2018 El Dorado Hills, CA – Consensus Orthopedics, Inc. (“Consensus”), an innovative orthopedics company, has been selected to present in the Life Science Intelligence Q2 2018 Emerging Medical Technologies Spotlight. The event is scheduled for Friday, June 29, 2018 at 1 p.m. EDT (10:00 a.m. PDT).  Access to the Consensus presentation and executive summary...

MedPharm Licenses Its MedSpray® ‘Patch-in-a-Can’ Technology to Virpax Pharmaceuticals for Non-Opioid Pain Management Products

GUILDFORD, UK – June 28, 2018 -- MedPharm, the world leader in topical and transdermal development,  licensed its unique MedSpray® technology to Virpax Pharmaceuticals (“Virpax”), a company based in Pennsylvania, US that is specialising in developing pharmaceutical products for pain management by using new drug delivery systems. MedSpray is covered by worldwide pate...

Wednesday 27th June 2018

First Wave Expands into Kaiser Permanente Network - Relationship Provides Entry into the Acute Care Market

June 27, 2018 – Batavia, New York – First Wave Products Group, LLC, a subsidiary of First Wave Technologies, Inc. (“First Wave” and “company”), announces that the company has expanded its customer base by signing a new client within the Kaiser Permanente hospital network.   The new client, The Kaiser Permanente Antioch Medical Center, located on t...

Tuesday 26th June 2018

Follicum successfully develops direct-to-scalp formulation to replace intradermal injections for first-in-class peptide-based FOL-005 hair loss drug candidate

June 26th 2018: Follicum AB ("Follicum" or "Company") today announced that the company has developed a new cosmetically appealing direct-to-scalp formulation of its leading peptide drug candidate FOL-005 for topical treatment of hair loss which will be used in future clinical trials. In Follicum's ongoing Phase IIa study, patients with hair loss are being treated wit...

Biotech Crop Adoption Leads to Greater Sustainability and Socioeconomic Opportunities for Global Farmers and Citizens - PG Economics & ISAAA

   Two new studies show continued environmental and social benefits of biotech crop use and adoption (June 26, 2018) – Today, the International Service for the Acquisition of Agri-biotech Applications (ISAAA) and PG Economics, Ltd. released new studies highlighting the continued social, environmental and economic benefits of the global adoption of

Quick Search


News Quicklinks